Skip to main content
TipRanks
Go Ultimate75% OFF

OncoZenge AB (8LY) AI Stock Analysis

0 Followers
DE:8LY

OncoZenge AB

(Frankfurt:8LY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-Free Balance SheetThe current debt-free position and positive equity provide financial flexibility while the company develops its oncology products. Low leverage reduces interest burden and refinancing pressure, giving management more room to allocate capital toward commercialization and operational needs.
Negative Factors
Persistent Cash BurnMaterially negative operating and free cash flow show that the business is not yet funding itself from operations. Continued cash burn can require additional financing or a rapid improvement in revenue and costs, potentially limiting strategic flexibility over the coming quarters.

OncoZenge AB (8LY) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:8LY-36.32%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.95M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.4
Beta (1Y)
0.71
Revenue Growth
122.10%
EPS Growth
-242.46%
Country
Germany
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinica...

OncoZenge AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:8LY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 386.26M2.0163.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IMMUSE:IMMU48NeutralSEK 253.42M-2.23-19.14%――13.06%
SE:ISOFOLSE:ISOFOL48NeutralSEK 339.08M-5.64-58.68%――35.02%
SE:ELICSE:ELIC47NeutralSEK 166.84M-7.07-56.09%――14.10%
SE:ONCOSE:ONCO44NeutralSEK 763.93M-2.81――65.37%43.28%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:8LYSE:ONCOSE:ISOFOLSE:ELICSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:8LY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:8LYOncoZenge AB0.28-0.15-34.52%
SE:ONCOOncopeptides AB1.77-3.04-63.20%
SE:ISOFOLIsofol Medical AB1.060.3651.36%
SE:ELICElicera Therapeutics AB2.50-2.78-52.66%
SE:IMMUImmunicum AB4.00-1.54-27.89%
SE:CANTACantargia AB1.37-2.05-60.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.